Corpus ID: 43356747

ARTHRITIS WITH ORAL TYPE I 1 COLLAGEN Results of a Multicenter , Double-Blind , Placebo-Controlled Trial

  title={ARTHRITIS WITH ORAL TYPE I 1 COLLAGEN Results of a Multicenter , Double-Blind , Placebo-Controlled Trial},
  author={M. L. Barnett and J. Kremer and E. Clair and Daniel and 0. and Clegg and E. Finger and A. Morales and LE CHRISTINEH. and D. Trentham and D. Furst and M. Weisman and M. Fletcher and S. Chasan-Taber},
Objective. Oral administration of cartilagederived type I1 collagen (CII) has been shown to ameliorate arthritis in animal models of joint inflammation, and preliminary studies have suggested that this novel therapy is clinically beneficial and safe in patients with rheumatoid arthritis (RA). The present study was undertaken to test the safety and efficacy of 4 different dosages of orally administered CII in patients with RA. Methods. Two hundred seventy-four patients with active RA were… Expand

Figures and Tables from this paper


A pilot trial of oral type II collagen in the treatment of juvenile rheumatoid arthritis.
Oral CCII may be a safe and effective therapy for JRA, and its use in this disease warrants further investigation. Expand
Effects of oral administration of type II collagen on rheumatoid arthritis.
Clinical efficacy of an oral tolerization approach for rheumatoid arthritis is demonstrated and a decrease in the number of swollen joints and tender joints occurred in subjects fed chicken type II collagen for 3 months but not in those that received a placebo. Expand
Efficacy of low-dose methotrexate in rheumatoid arthritis.
It is concluded that this trial provides evidence of the short-term efficacy of methotrexate in rheumatoid arthritis, but the mechanism of action is unknown and longer trials will be required to determine the ultimate safety and effectiveness of this drug. Expand
Treatment of active refractory rheumatoid arthritis with humanized monoclonal antibody CAMPATH-1H administered by daily subcutaneous injection.
C1H is a lymphocyte-depleting antibody that exhibits biologic potency when administered subcutaneously to patients with refractory RA and its use is associated with mild to moderate toxicity and short-term amelioration of disease activity. Expand
Gastric administration of type II collagen delays the onset and severity of collagen-induced arthritis in rats.
The results indicate that materials specifically cross-reactive with autoantigens can be absorbed through the gut and can modify susceptibility to autoimmune disease. Expand
Suppression of adjuvant arthritis in rats by oral administration of collagen
Oral CII could cure SD rats' AA and the experiment suggests that the CII may be used in treatment of human rheumatoid arthritis ( RA ). Expand
Suppression of antigen-induced arthritis in Lewis rats by oral administration of type II collagen.
Oral CII can suppress arthritis in an animal model in which immunity to collagen does not play a role, and the effect is dose dependent and occurs at lower doses of CII. Expand
Suppression of type II collagen-induced arthritis by intragastric administration of soluble type II collagen.
Although oral administration of protein antigens may lead to specific immunologic unresponsiveness, this method of immunoregulation has not been applied to models of autoimmune disease and the overall magnitude of the antibody response is not significantly reduced in collagen-fed mice as compared to controls. Expand
Autoimmunity to type II collagen an experimental model of arthritis
Since homologous type II collagen emulsified in oil without bacterial preparations regularly causes the disease, this new animal model of arthritis represents a unique example of experimentally-inducible autoimmunity to a tissue component. Expand
Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs, based on the findings in patients treated with placebo. The Cooperative Systematic Studies of Rheumatic Diseases Group.
The proposed index appears to be useful in estimating the probability that an RA patient will improve if taking a placebo during a DMARD trial, and may be a useful tool for analysis of DMARD studies. Expand